www.scottishmedicines.org.uk

Healthcare Improvement Scotland | SMC Advice on new medicines

Product update
SMC2320

leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe

Takeda UK Limited

15 January 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

leuprorelin acetate (Prostap®) is accepted for use within NHSScotland.

Indication under review: as treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.

Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 01 December 2020.

Chairman
Scottish Medicines Consortium